179 related articles for article (PubMed ID: 38003971)
21. MERTK Promotes Resistance to Irreversible EGFR Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancers Expressing Wild-type
Yan D; Parker RE; Wang X; Frye SV; Earp HS; DeRyckere D; Graham DK
Clin Cancer Res; 2018 Dec; 24(24):6523-6535. PubMed ID: 30194074
[TBL] [Abstract][Full Text] [Related]
22. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
Gelatti ACZ; Drilon A; Santini FC
Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888
[TBL] [Abstract][Full Text] [Related]
23. Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model.
Diaz R; Nguewa PA; Parrondo R; Perez-Stable C; Manrique I; Redrado M; Catena R; Collantes M; Peñuelas I; Díaz-González JA; Calvo A
BMC Cancer; 2010 May; 10():188. PubMed ID: 20459769
[TBL] [Abstract][Full Text] [Related]
24. EGFR mutation mediates resistance to EGFR tyrosine kinase inhibitors in NSCLC: From molecular mechanisms to clinical research.
Dong RF; Zhu ML; Liu MM; Xu YT; Yuan LL; Bian J; Xia YZ; Kong LY
Pharmacol Res; 2021 May; 167():105583. PubMed ID: 33775864
[TBL] [Abstract][Full Text] [Related]
25. Drug resistance of targeted therapy for advanced non-small cell lung cancer harbored EGFR mutation: from mechanism analysis to clinical strategy.
Zhao Y; Wang H; He C
J Cancer Res Clin Oncol; 2021 Dec; 147(12):3653-3664. PubMed ID: 34661758
[TBL] [Abstract][Full Text] [Related]
26. miR-762 activation confers acquired resistance to gefitinib in non-small cell lung cancer.
Ge P; Cao L; Chen X; Jing R; Yue W
BMC Cancer; 2019 Dec; 19(1):1203. PubMed ID: 31823748
[TBL] [Abstract][Full Text] [Related]
27. Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma.
Rybarczyk-Kasiuchnicz A; Ramlau R; Stencel K
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435596
[TBL] [Abstract][Full Text] [Related]
28. Epidermal growth factor receptor and K-Ras mutations and resistance of lung cancer to insulin-like growth factor 1 receptor tyrosine kinase inhibitors.
Kim WY; Prudkin L; Feng L; Kim ES; Hennessy B; Lee JS; Lee JJ; Glisson B; Lippman SM; Wistuba II; Hong WK; Lee HY
Cancer; 2012 Aug; 118(16):3993-4003. PubMed ID: 22359227
[TBL] [Abstract][Full Text] [Related]
29. Long Non-Coding RNA CRNDE Is Involved in Resistance to EGFR Tyrosine Kinase Inhibitor in EGFR-Mutant Lung Cancer via eIF4A3/MUC1/EGFR Signaling.
Takahashi S; Noro R; Seike M; Zeng C; Matsumoto M; Yoshikawa A; Nakamichi S; Sugano T; Hirao M; Matsuda K; Hamada M; Gemma A
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33924522
[TBL] [Abstract][Full Text] [Related]
30. [Blaps rynchopetera affects proliferation, migration, and invasion of non-small cell lung cancer: a study based on network pharmacology and in vivo and in vitro experiments].
Li XY; Ma K; Yan JN; You FC; Ma L
Zhongguo Zhong Yao Za Zhi; 2023 Jul; 48(13):3576-3588. PubMed ID: 37474991
[TBL] [Abstract][Full Text] [Related]
31. Application of liquid biopsy-based targeted capture sequencing analysis to improve the precision treatment of non-small cell lung cancer by tyrosine kinase inhibitors.
Zhang L; Coffin J; Formenti K; Chu Q; Izevbaye I
BMJ Open Respir Res; 2022 Jan; 9(1):. PubMed ID: 35091437
[TBL] [Abstract][Full Text] [Related]
32. Marked synergy by vertical inhibition of EGFR signaling in NSCLC spheroids shows SOS1 is a therapeutic target in EGFR-mutated cancer.
Theard PL; Sheffels E; Sealover NE; Linke AJ; Pratico DJ; Kortum RL
Elife; 2020 Sep; 9():. PubMed ID: 32897190
[TBL] [Abstract][Full Text] [Related]
33. AT-101 enhances gefitinib sensitivity in non-small cell lung cancer with EGFR T790M mutations.
Zhao R; Zhou S; Xia B; Zhang CY; Hai P; Zhe H; Wang YY
BMC Cancer; 2016 Jul; 16():491. PubMed ID: 27431492
[TBL] [Abstract][Full Text] [Related]
34. Identification of genetic alterations associated with primary resistance to EGFR-TKIs in advanced non-small-cell lung cancer patients with EGFR sensitive mutations.
Wang F; Diao XY; Zhang X; Shao Q; Feng YF; An X; Wang HY
Cancer Commun (Lond); 2019 Mar; 39(1):7. PubMed ID: 30823937
[TBL] [Abstract][Full Text] [Related]
35. Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC).
Hsu PC; Jablons DM; Yang CT; You L
Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31387256
[TBL] [Abstract][Full Text] [Related]
36. Up-Regulation of MiRNA-125a-5p Inhibits Cell Proliferation and Increases EGFR-TKI Induced Apoptosis in Lung Cancer Cells.
Amri J; Molaee N; Karami H
Asian Pac J Cancer Prev; 2019 Nov; 20(11):3361-3367. PubMed ID: 31759360
[TBL] [Abstract][Full Text] [Related]
37. Epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation testing in adults with locally advanced or metastatic non-small cell lung cancer: a systematic review and cost-effectiveness analysis.
Westwood M; Joore M; Whiting P; van Asselt T; Ramaekers B; Armstrong N; Misso K; Severens J; Kleijnen J
Health Technol Assess; 2014 May; 18(32):1-166. PubMed ID: 24827857
[TBL] [Abstract][Full Text] [Related]
38. Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy.
Liao BC; Lin CC; Lee JH; Yang JC
Lung Cancer; 2017 Aug; 110():7-13. PubMed ID: 28676222
[TBL] [Abstract][Full Text] [Related]
39. Specific Gene Co-variation Acts Better Than Number of Concomitant Altered Genes in Predicting EGFR-TKI Efficacy in Non-small-cell Lung Cancer.
Zhu YJ; Qu X; Zhan DD; Chen HH; Li HP; Liu LR; Chen X; Liu YH; Li Y; Bai JP; Ye S; Zhang HB
Clin Lung Cancer; 2021 Jan; 22(1):e98-e111. PubMed ID: 33067127
[TBL] [Abstract][Full Text] [Related]
40. Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario.
Russo A; Franchina T; Ricciardi G; Battaglia A; Picciotto M; Adamo V
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30901844
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]